Morphologic Stomach Findings in Rats and Mice Treated with the H 2 Receptor Antagonists,ICI 125,211 and ICI 162,846

Abstract

The gross and histopathologic findings seen in the stomachs of rats and mice treated with 2 different H₂ receptor antagonists are presented. Studies with the first drug, ICI 125,211, elicited dysplasia/carcinoma lesions in 17 of 828 treated rats with 12 of the 17 lesions occurring in the pyloric region of the stomach. No tumors occurred in mice on study for 18 months. Studies conducted with another drug candidate, ICI 162,846, produced neuroendocrine carcinomas in the stomach of rats and mice. Twenty-five rats out of 312 treated male and female rats had neuroendocrine carcinomas in the gastric fundus with a higher tumor incidence in females. In a 24-month mouse study with ICI 162,846, 45 of 300 treated mice developed neuroendocrine carcinomas in the gastric fundus with a higher incidence in males.

References

1. Betton GR. (1987). Personal communication.

2. Bralow SP , Gruenstein M , Meranze DR , Bonakdarpour A , and Shimkin MB (1970). Adenocarcinoma of glandular stomach and duodenum in Wistar rats ingesting N-methyl-N-nitro-N-nitrosoguanidine, histopathology and associated secretory changes. Cancer Res. 30: 1215–1222.

3. Crissman JW , Robertson JL , Brooks JS , and Streett CS (1987). Gastric neuroendocrine carcinomas in B6C3F1 mice given a gastric H2 antagonist, ICI 162,846 in a 2-year dietary oncogenicity study. Toxicol. Pathol. 15: 366.

4. Deschner EE , Tamura K , and Bralow SP (1979). Sequential histopathology and cell kinetic changes in rat pyloric mucosa during gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine. J. Natl. Cancer Inst. 63: 171–179.

5. Ekman L , Hansson E , Havu N , Carlsson E , and Lundberg C (1985). Toxicological studies on omeprazole. Scand. J. Gastroenterol. (Suppl.) 108: 56–69.

6. Elder JB (1985). Inhibitions of acid and gastric carcinoids. Gut 26: 1279–1283.

7. Hirth RS (1987). ECL cell proliferation and neoplasia associated with the H2 receptor antagonist, BL-6341. Toxicol. Pathol. 15: 364.

8. Kunze E , Schauer A , Eder M , and Seefeldt CJ (1979). Early sequential lesions during development of experimental gastric cancer with special reference to dysplasia. J. Cancer Res. Clin. Oncol. 95: 247–264.

9. Larsson H , Carlsson E , Mattson H , Lundell L , Sundler F , Gunhild S , Wallmark B , Takehiko W , and Hikanson R (1986). Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Gastroenterology 90: 391–399.

10.

10. Morson BC , Sobin LH , Grundmann E , Johansen A , Nagayo T , and Serck-Hanssen A (1980). Precancerous conditions and epithelial dysplasia in the stomach. J. Clin. Path. 33: 711–721.

11.

11. Poynter D , Pick CR , and Harcourt RA (1985). Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumors in the rat. Gut 26: 1284–1295.

12.

12. Poynter D , Selway SA , Papworth SA , and Riches SR (1986). Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockade. Gut 27(11): 1338–1346.

13.

13. Robertson JL, Crissman JW, Brooks JS, and Streett CS (1988). Gastric neuroendocrine carcinomas induced in rats by administration of the gastric H2-receptor antagonist ICI 162,846 (in preparation).

14.

14. Saito T , Inokuchi K , Takayama S , and Sugimura T (1970). Sequential morphological changes in N-methyl-N'-nitrosoguanidine carcinogenesis in the glandular stomach of rats. J. Natl. Cancer Inst. 44: 769–783.

15.

15. Streett CS , Cimprich RE , and Robertson JL (1984). Pathologic findings in the stomachs of rats treated with H2-receptor antagonist tiotidine. Scand. J. Gastroenlerol. (Suppl. 101) 19: 109–117.

16.

16. Sugimura T , Fujimura S , and Baba T (1970). Tumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Res. 30: 455–465.